Clinical Drug Investigation

, Volume 33, Issue 12, pp 939–940 | Cite as

Hemoglobin Stability and Patient Satisfaction After Switch to C.E.R.A. Therapy: A Multicenter, Observational Study

Letter to the Editor
First Online:
  • 113 Downloads

Keywords

Chronic Kidney Disease Chronic Kidney Disease Patient Erythropoiesis Stimulate Agent Welwyn Garden City Clinical Drug Investigation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Heidenreich S, Leistikow F, Zinn S; SUPRA Study Group, et al. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study. Clin Drug Investig. 2012;32(2):99–110.Google Scholar
  2. 2.
    Levin NW, Fishbane S, Cañedo FV; MAXIMA Study Investigators, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370(9596):1415–21.Google Scholar
  3. 3.
    Sulowicz W, Locatelli F, Ryckelynck JP; PROTOS Study Investigators, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2(4):637–46.Google Scholar
  4. 4.
    Carrera F, Lok CE, de Francisco A; PATRONUS Investigators, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25(12):4009–17.Google Scholar
  5. 5.
    Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2011;26(12):3980–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Locatelli F, Villa G, de Francisco AL; on behalf of the BA16286 study investigators, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23(5):969–79.Google Scholar
  7. 7.
    Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin. 2010;26(5):1083–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Weinreich T, Leistikow F, Hartmann HG, et al. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodial Int. 2012;16(1):11–9.PubMedGoogle Scholar
  9. 9.
    Ruiz P, Balcke P, Martinez JM, et al. Tolerability of the epoetin-beta multidose formulation (Reco-Pen) in patients with renal anaemia. Clin Drug Invest. 2000;20(3):152–8.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Nephrologisches ZentrumDaunGermany
  2. 2.Nephrologisches ZentrumDieburgGermany

Personalised recommendations